CoChat

BOREAS: A Global, Phase III Study of the MDM2 Inhibitor Navtemadlin (KRT-232) in Relapsed/Refractory Myelofibrosis

Open access

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Abstract

Patients with myelofibrosis (MF) who discontinue ruxolitinib due to progression/resistance have poor prognoses. JAK inhibitors control symptoms and reduce spleen volumes with limited impact on underlying disease pathophysiology. Murine double minute 2 (MDM2), a negative regulator of p53, is overexpressed in circulating malignant CD34+ MF cells. The oral MDM2 inhibitor navtemadlin (KRT-232) restores p53 activity to drive apoptosis of wild-type TP53 tumor cells by inducing expression of pro-apoptotic Bcl-2 family proteins. Navtemadlin demonstrated promising clinical and disease-modifying activity and acceptable safety in a phase II study in patients with relapsed/refractory MF. The randomized phase III BOREAS study compares the efficacy and safety of navtemadlin to best available therapy in patients with MF that is relapsed/refractory to JAK inhibitor treatment. Clinical Trial Registration: NCT03662126 (ClinicalTrials.gov).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2217/fon-2022-0901

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Research works printed but not linked: 1

  1. Al-Ali HK , DelgadoRG, LangeAet al. KRT-232, a first-in-class, murine double minute 2 inhibitor (MDM2i), for myelofibrosis (MF) relapsed or refractory (R/R) to Janus-associated kinase inhibitor (JAKi) treatment (TX). HemaSphere. 4, 65. Abstract S215 (2020).

Cited by

See all 41

Metadata

Authors
Verstovsek, S., Al-Ali, H. K., Mascarenhas, J., Perkins, A., Vannucchi, A. M., Mohan, S. R., Scott, B. L., Woszczyk, D., Koschmieder, S., García-Delgado, R., László, R., McGreivy, J. S., Rothbaum, W. P., & Kiladjian, J.-J.
Affiliations
  • The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
  • Krukenberg Cancer Center,University Hospital, Halle, 33790, Germany
  • Icahn School of Medicine at Mount Sinai (US)
  • Monash University (AU)
  • University of Florence (IT)
  • Vanderbilt University Medical Center (US)
  • Fred Hutch Cancer Center (US)
  • University of Opole (PL)
  • RWTH Aachen University (DE)
  • Virgen de la Victoria University Hospital, Málaga, 29010, Spain
  • Josa András Teaching Hospital, Nyíregyháza, 4400, Hungary
  • Kartos Therapeutics, Inc. (United States) (US)
  • Université Paris Cité (FR)
Venue
Future Oncology
Published
2022-11-23
Volume
18
Issue
37
Pages
4059-4069
ISSN
  • 1479-6694 (ISSN-L)
  • 1744-8301
OpenAlex
W4309728705
Cited by
41
References
39
Citations by year
2026: 12 · 2025: 15 · 2024: 4 · 2023: 10
FWCI
1.20
Type
journal article
Language
en
Open access
Locations
  • Future Oncology (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Florence Research (University of Florence) (submittedVersion, cc-by-nc-nd)
  • University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion, other-oa)
  • RWTH Publications (RWTH Aachen) (submittedVersion, other-oa)
  • RWTH Publications (RWTH Aachen)
Funders
Kartos Therapeutics
Topics
  • Health Sciences › Medicine › Hematology › Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
Keywords
MDM2 inhibitors, myelofibrosis, p53 restoration, apoptosis, Bcl-2 family proteins, JAK inhibitor resistance, ruxolitinib, spleen volume, disease-modifying therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BOREAS: A Global, Phase III Study of the MDM2 Inhibitor Navtemadlin (KRT-232) in Relapsed/Refractory Myelofibrosis. https://app.cochat.ai/papers/10.2217/fon-2022-0901
The paper
Verstovsek, S., Al-Ali, H. K., Mascarenhas, J., Perkins, A., Vannucchi, A. M., Mohan, S. R., Scott, B. L., Woszczyk, D., Koschmieder, S., García-Delgado, R., László, R., McGreivy, J. S., Rothbaum, W. P., & Kiladjian, J.-J. (2022). BOREAS: A Global, Phase III Study of the MDM2 Inhibitor Navtemadlin (KRT-232) in Relapsed/Refractory Myelofibrosis. Future Oncology. https://doi.org/10.2217/fon-2022-0901

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.